Valo Therapeutics

About:

Valo Therapeutics is an immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines.

Website: https://www.valotx.com/

Twitter/X: ValoTherapeuti1

Top Investors: European Innovation Council, Business Finland

Description:

Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer.